GC Cell Signs MOU with MICS for Global Multi-country Clinical Trial Service Collaboration

Global clinical trial sample analysis organization GC Cell announced on February 10 that on February 9 it signed a memorandum of understanding (MOU) with Europe-based clinical trial and diagnostic service specialist Medicover Integrated Clinical Services (MICS) for business cooperation in global multi-country clinical trial services.

Through this MOU, the two companies plan to establish a collaborative framework that covers Europe, the United States, and the Asia-Pacific (APAC) region, and, based on their accumulated experience in clinical trial operations and customer communication capabilities in each region, enhance cross-regional communication efficiency and project operation stability when executing global clinical trial projects.

The main points of the MOU include: cooperation on clinical trial operations and sample analysis across regions; support for clinical trial project management and linkage of regional customer communication; joint marketing collaboration; joint customer development and market expansion; and strengthening service competitiveness by linking test items and improving analytical efficiency.

In particular, this MOU combines MICS's clinical trial operation experience and local network in Europe and the United States with GC Cell's capabilities in clinical trial sample analysis and project management know-how in Asia, including Korea. It is expected to provide global clients with an optimized clinical trial environment in which clinical operations and analysis across regions are organically connected.

Łukasz Hubisz, General Manager of MICS, said, "This agreement is a collaboration to improve the operational efficiency of global clinical trial projects, based on the experience of both companies that have actually conducted clinical trials in each region," adding, "Through cooperation with GC Cell, we will strengthen communication with customers in Asia, including Korea, and more smoothly support the conduct of global clinical trials."

Cho Kwangoo, CEO of GC Cell, said, "This agreement is an important first step in solidifying a clinical partnership that connects Europe and Asia," and added, "Through strategic cooperation with MICS, we will present a new standard for conducting global clinical trials and deliver tangible analytical outcomes to our clients."

Meanwhile, MICS is part of the Medicover Healthcare Group and has successfully carried out various clinical trial projects in Europe. It provides services specialized in clinical research to a wide range of clients in pharmaceuticals, diagnostics, medical devices, and contract research organizations (CROs). Its main services include central lab operations, clinical trial site management, and precision medicine. It delivers high-quality services by strategically leveraging Medicover's state-of-the-art diagnostic equipment, medical clinics, and hospital infrastructure.

GC Cell is a clinical trial sample analysis organization that has obtained certification in all areas of Good Clinical Laboratory Practice (GCLP) from the Ministry of Food and Drug Safety, and provides customized clinical CRO services that meet global standards for the entire clinical trial life cycle from Phase 1 to Phase 4. Based on various analytical platforms that comply with global quality standards, such as the introduction of ddPCR equipment, as well as specialized sample analysis and analytical method development services, it supports clinical trial sample analysis not only for domestic pharmaceutical and biotech companies, but also for partners across Asia and around the world.

This content was produced with the assistance of AI translation services.